Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722174 · ClinicalTrials.gov registry record
Fingerprinting of Impulsivity
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 141
- Enrollment target
NCT02722174: Completed study, sponsored by Boehringer Ingelheim.
NCT02722174 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02722174 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
The study aims to examine a battery of behavioral and questionnaire measures in 4 disorders clinically associated with impulsivity and in health controls, to: 1) investigate if the different populations have a distinct behavioral profile, and 2) to investigate if there are specific measures that are reliable and sensitive measures of impulsivity across diagnoses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2016-07-22 |
| Est. Completion | 2018-09-06 |
What the finished NCT02722174 record still lists
NCT02722174 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02722174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02722174 about?
NCT02722174 is a clinical study titled "Fingerprinting of Impulsivity". The study aims to examine a battery of behavioral and questionnaire measures in 4 disorders clinically associated with impulsivity and in health controls, to: 1) investigate if the different populations have a distinct behavioral profile, and 2) to investigate if there are specific measures that are...
What is the current status of trial NCT02722174?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2016-07-22. Estimated completion is 2018-09-06.
Who is sponsoring clinical trial NCT02722174?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI